Table 1 Patient demographics
Variable | Training (n = 41) | Test (n = 23) | Combined (n = 64a) |
|---|---|---|---|
Age at diagnosis, mean (range) years | 13.9 (7.5–18.1) | 13.7 (9.5–18.1) | 13.8 (7.5–18.1) |
Sampling date, postdiagnosis (range) days | 15 (0–62) | 5 (0–32) | 12 (0–62) |
Number (%) females | 37 (90) | 20 (87) | 57 (89) |
ANA-positive patients (%) | 40 (98) | 23 (100) | 63 (98) |
dsDNA antibody-positive patients (%) | 35 (83) | 19 (83) | 53 (83) |
Class III/IV lupus nephritis-biopsy provenb (%) | 23 (56) | 8 (35) | 31 (48) |
Mean (range) SLEDAI score | 14 (4–30) | 14 (4–29) | 14 (4–30) |
Treatment at sample: | Â | Â | Â |
 PO steroids (%) | 17 (41) | 4 (20) | 21 (33) |
 IV steroids (%) | 18 (44) | 1 (5) | 19 (30) |
 HCQ (%) | 18 (44) | 8 (40) | 26 (41) |
 Other IS (%) | 6 (15) | 0 (0) | 6 (9) |
 None | 10 (24) | 12 (60) | 22 (34) |
Hispanic (%) | 16 (39) | 9 (39) | 25 (39) |
Asian/Pacific Islander (%) | 12 (29) | 8 (35) | 20 (31) |
Non-Hispanic Caucasian (%) | 10 (24) | 5 (22) | 15 (23) |
Black (%) | 2 (5) | 1 (4) | 3 (5) |